# Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial

## TL;DR

This study explores immune biomarkers in kidney cancer patients treated with nivolumab after tyrosine kinase inhibitors to predict treatment outcomes.

## Contribution

The study identifies immune cell subsets in blood and tissue that correlate with clinical outcomes in patients receiving nivolumab.

## Key findings

- Responders to nivolumab showed a significant reduction in CD4+TEF cell fraction at 3 months.
- Higher immune cell densities in tissue samples correlated with responders to nivolumab.
- CD127+CD4+ T cells were enriched in patients with immune-related adverse effects.

## Abstract

Predictive biomarkers for immune checkpoint blockade in the second-line treatment of metastatic renal cell carcinoma (mRCC) are lacking.

Patients with histologically confirmed RCC who started nivolumab after at least 4 months of tyrosine kinase inhibitors (TKIs) were recruited for this study. Serial tissue and blood samples were collected for immune biomarker evaluation. The primary endpoint was to determine the association of specific T-cell subsets with clinical outcomes tested using Wilcoxon rank sum for clinical benefit rate (CBR) and log-rank test for progression-free survival (PFS).

Twenty patients were included in this trial with a median age of 64 years and followed-up for a median of 12 months. The median PFS for patients who received TKI was 13.8 months, while for those subsequently treated with nivolumab following TKI therapy, the median PFS was 2.6 months. CBR of nivolumab was 20% with two partial responses. Functionally active programmed cell death protein 1+ CD4+ T cells were enriched in non-responders (q = 0.003) and associated with worse PFS on nivolumab (P = 0.04). Responders showed a significant reduction in the effector CD4+T-cell (TEF) fraction compared to non-responders at 3 months on nivolumab (0.40 versus 0.80, P = 0.0005). CD127+CD4+ T cells were enriched in patients who developed immune-related adverse effects (q = 0.003). Using in-house validated multiplex immunohistochemistry for six markers, we measured tumour-associated immune cell densities in tissue samples. Responders to nivolumab showed a significantly higher mean of immune cell densities in tissue samples compared to non-responders (346 versus 87 cells/mm2, P = 0.04).

In this small study, analysis of tissue-based and peripheral blood immune cell subsets predicted clinical outcomes of nivolumab. Further studies are warranted with larger populations to validate these observations.

•Significant reduction was found in CD4+TEF cell fraction in responders at 3 months on nivolumab.•CD127+CD4+ T cells enriched in patients with immune-related adverse effects to nivolumab.•Higher mean immune cell densities in tissue samples correlated with responders to nivolumab.•The study suggests the potential of immune cell subsets in predicting clinical outcomes.

Significant reduction was found in CD4+TEF cell fraction in responders at 3 months on nivolumab.

CD127+CD4+ T cells enriched in patients with immune-related adverse effects to nivolumab.

Higher mean immune cell densities in tissue samples correlated with responders to nivolumab.

The study suggests the potential of immune cell subsets in predicting clinical outcomes.